Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Study: Bicycling May Trigger a Herpes Inflammation of the Brain; CBCD Reviews the Medical Evidence
  • USA - English


News provided by

CBCD

Jan 08, 2015, 12:30 ET

Share this article

Share toX

Share this article

Share toX


Rochester, NY (PRWEB) January 08, 2015 -- “Infected with the herpes virus (HSV-1, or HSV-2)? The CBCD recommends taking Novirin or Gene-Eden-VIR.” - Greg Bennett, CBCD

We recommend that individuals infected with the herpes virus take Novirin or Gene-Eden-VIR. - Greg Bennett, CBCD

Post this

The latent herpes virus (HSV-2) can reactivate, and cause an inflammation of the layers lining the brain when an infected individual engages in strenuous bicycling. This condition is called aseptic meningitis. For example, Dr. Olaf Stuv and colleagues wrote in a study that herpes simplex type 2 is linked to “aseptic meningitis in the setting of heat exposure and bicycling.” (1) Dr. Stuv is from the Department of Neurology and Neurotherapeutics at the University of Texas Southwestern Medical Center at Dallas in Dallas, Texas. According to the study authors, the reactivation of the latent HSV-2 may be caused by “the dual activation of mechanical and temperature receptors in dorsal root ganglia (nerves).” In other words, the physical stress of bicycling, combined with the heat generated by the exercise may cause the reactivation of the latent herpes virus, which then travels to the brain where it causes inflammation. Symptoms include: “fever, chills, stomach ache, painful headache, body aches, sensitivity to light, loss of appetite, vomiting, (and) fatigue.” (See healthline.com, last reviewed on August 7, 2012) (2) The Center for the Biology of Chronic Disease (CBCD) recommends that infected individuals take Novirin or Gene-Eden-VIR, which have a natural, antiviral formula that was shown to effectively reduce HSV symptoms in two separate post-marketing studies that followed FDA guidelines.

Click to learn more about HSV symptoms.

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the family of herpes viruses, including HSV-1 and HSV-2. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with (HSV-1 or HSV-2)…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3) The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinensis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims.

What is meningitis?

The Mayo Clinic says that “Meningitis is an inflammation of the membranes (meninges) surrounding your brain and spinal cord. The swelling associated with meningitis often triggers the "hallmark" signs and symptoms of this condition, including headache, fever and a stiff neck. Most cases of meningitis in the U.S. are caused by a viral infection.” (See Mayoclinic.org, from March 19, 2013) (4)

The herpes family of viruses is known to cause several different types of meningitis. In fact, meningitis.org notes that “Herpes viruses are the other common cause of viral meningitis in adolescents and adults in developed countries. Herpes viruses include the herpes simplex viruses (HSVs) and varicella zoster virus - the same virus that causes chickenpox and shingles. HSVs can cause meningitis or encephalitis (inflammation of the brain itself, which is much more serious). HSV encephalitis is mainly caused by HSV-1 (which is also the cause of most cold-sores), whereas meningitis is more often caused by HSV-2 (the cause of most genital herpes). HSV viruses have been linked to Recurrent Lymphocytic Meningitis, also known as Mollaret’s meningitis. It is characterised by sudden attacks of meningitis symptoms that usually last for 2-7 days and are separated by symptom free intervals lasting for weeks, months or years.” (See Meningitis.org) (5)

What treatments are available for herpes infections?

“Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day.” (See Pharmacology & Pharmacy from September 2013) (3). There are also the natural supplements Novirin and Gene-Eden-VIR, which have a formula that was designed to help the immune system target the herpes virus when it is in a latent form.

“We recommend that individuals infected with the herpes virustake Novirin or Gene-Eden-VIR.” – Greg Bennett, CBCD

Interested individuals can view the studies published on these natural antiviral products here: http://cbcd.net/Gene-Eden-VIR-Clinical-Study.php and http://cbcd.net/Gene-Eden-VIR-Decreases-Fatigue-Clinical-Study.php.

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Olaf Stuve1234*, Ellen Marder12, Annette Okai5, Mark Stettner4 and Bernd C Kieseier4 "Heat exposure and bicycling trigger recurrent aseptic meningitis: a case report." BMC Neurology 2014, 14:1061 http://www.biomedcentral.com/1471-2377/14/1061/abstract#

(2) Healthline.com - Selner, M. "Aseptic Meningitis." Published on August 7, 2012. http://www.healthline.com/health/aseptic-meningitis#Overview1

(3) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

(4) Mayoclinic.org - "Meningitis" - from March 19, 2013.
            http://www.mayoclinic.org/diseases-conditions/meningitis/basics/definition/con-20019713

(5) Meningitis.org - Viral Meningitis
     http://www.meningitis.org/disease-info/types-causes/viral-meningitis

Greg Bennett, CBCD, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.